GA
ALNY icon

Gateway Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gateway Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,180
Closed -$236K – 107
2023
Q1 		$236K Buy
1,180
+17
+1% +$3.57K 0.05% 83
2022
Q4 		$276K Buy
+1,163
New +$248K 0.07% 60

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Gateway Advisory's ALNY Position: Q2 2023 in Review

Gateway Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 1,180 shares — an estimated $236K sold.

Gateway Advisory first reported a position in ALNY in Q4 2022 and held it in 2 quarters. The position peaked at $276K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

  • Gateway Advisory reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Gateway Advisory sold 1,180 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $236K.
  • Gateway Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Gateway Advisory's Alnylam Pharmaceuticals position peaked at $276K in Q4 2022.
  • 476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Gateway Advisory's 13F filing for Q2 2023, filed 10 Aug 2023.